Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
John P Leonard, Ann S LaCasce, Mitchell R Smith, Ariela Noy, Lucian R Chirieac, Scott J Rodig, Jian Q Yu, Shankar Vallabhajosula, Heiko Schoder, Patricia English, Donna S Neuberg, Peter Martin, Michael M Millenson, Scott A Ely, Rachel Courtney, Naveed Shaik, Keith D Wilner, Sophia Randolph, Annick D Van den Abbeele, Selina Y Chen-Kiang, Jeffrey T Yap, Geoffrey I Shapiro, John P Leonard, Ann S LaCasce, Mitchell R Smith, Ariela Noy, Lucian R Chirieac, Scott J Rodig, Jian Q Yu, Shankar Vallabhajosula, Heiko Schoder, Patricia English, Donna S Neuberg, Peter Martin, Michael M Millenson, Scott A Ely, Rachel Courtney, Naveed Shaik, Keith D Wilner, Sophia Randolph, Annick D Van den Abbeele, Selina Y Chen-Kiang, Jeffrey T Yap, Geoffrey I Shapiro
Abstract
Mantle cell lymphoma (MCL) carries an unfavorable prognosis and requires new treatment strategies. The associated t(11:14) translocation results in enhanced cyclin D1 expression and cyclin D1-dependent kinase activity to promote cell-cycle progression. A pharmacodynamic study of the selective CDK4/6 inhibitor PD0332991 was conducted in 17 patients with relapsed disease, using 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) and 3-deoxy-3[(18)F]fluorothymidine (FLT) positron emission tomography (PET) to study tumor metabolism and proliferation, respectively, in concert with pre- and on-treatment lymph node biopsies to assess retinoblastoma protein (Rb) phosphorylation and markers of proliferation and apoptosis. Substantial reductions in the summed FLT-PET maximal standard uptake value (SUV(max)), as well as in Rb phosphorylation and Ki-67 expression, occurred after 3 weeks in most patients, with significant correlations among these end points. Five patients achieved progression-free survival time of > 1 year (range, 14.9-30.1+ months), with 1 complete and 2 partial responses (18% objective response rate; 90% confidence interval, 5%-40%). These patients demonstrated > 70%, > 90%, and ≥ 87.5% reductions in summed FLT SUV(max) and expression of phospho-Rb and Ki67, respectively, parameters necessary but not sufficient for long-term disease control. The results of the present study confirm CDK4/6 inhibition by PD0332991 at a well-tolerated dose and schedule and suggest clinical benefit in a subset of MCL patients. This study is registered at www.clinicaltrials.gov under identifier NCT00420056.
Source: PubMed